Thank you to NeurologyLive for featuring, Dr. Sharron Gargosky, PhD, Chief Development Officer at Spinogenix, at the AAIC2025 in Toronto
Sharron highlights key findings from our Phase 2a study on SPG302, a first-in-class synaptic regenerative therapy in Alzheimer’s disease participants in Australia.
- The study enrolled all Alzheimer patients with mild to moderate disease who were given once daily tablets of SPG302
- The treatment was well tolerated with no serious adverse events
- Patients treated with SPG302 experienced an approximate 3-point improvement on the Mini
- Mental State Examination (MMSE)—a brief assessment of memory and other cognitive functions—within 4 weeks of treatment
With daily dosing, the effect was sustained through 6 months of trial